Australia

Found 8,143 articles

• Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma

  5/2/2023

  Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces a Key Opinion Leader (KOL) event will be hosted by Ladenburg Thalmann & Co, Inc., on Tuesday, May 9, 2023, from 11:30 AM – 1:00 PM ET.

• Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®

  5/1/2023

  Immutep Limited announces it has received regulatory approval from the Paul-Ehrlich-Institut, German Federal Institute for Vaccines and Biomedicines, to initiate INSIGHT-005, an investigator-initiated, open-label Phase I trial evaluating the safety and efficacy of eftilagimod alpha in combination with BAVENCIO® in up to 30 patients with metastatic urothelial carcinoma.

• First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide

  5/1/2023

   Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first patients have been imaged in Canada with its commercially available prostate cancer imaging agent, Illuccix® [kit for the preparation of gallium (68Ga) PSMA-11 for intravenous injection].

• Carina Biotech to Present Details of Planned Phase 1/2a Clinical Trial of LGR5-Targeted CAR-T Cell Therapy Candidate CNA3103 for Metastatic Colorectal Cancer at 2023 ASCO Annual Meeting

  5/1/2023

  Carina Biotech (Carina) today announced a poster presentation showcasing its planned Phase 1/2a clinical trial of its LGR5-targeted CAR-T cell therapy candidate CNA3103 in patients with metastatic colorectal cancer (mCRC) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting that will take place in Chicago, Illinois on June 2-6.

• New Publication Validates geneType for Melanoma Risk Assessment

  4/28/2023

  Genetic Technologies Limited is pleased to announce the publication of a research paper in the peer-reviewed journal Melanoma Research validating the geneType for Melanoma risk assessment test in one of the most commonly diagnosed cancers in the Western world, 3rd in Australia and 5th in the United States.

• Quarterly Activities and Cashflow Report

  4/28/2023

  Bionomics Limited, a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, released its Appendix 4C – Quarterly Cashflow Report.

• Opthea To Participate at the H.C. Wainwright BioConnect Conference at NASDAQ

  4/28/2023

  Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that management will participate in the one-on-one meeting portion of the H.C. Wainwright BioConnect Conference being held on May 2, 2023.

• IMG-004 demonstrated extended half-life and durable pharmacodynamic characteristics in a Phase 1 study

  4/28/2023

  Inmagene Biopharmaceuticals announced positive topline results from a Phase 1 study evaluating IMG-004 in healthy participants.

• Immutep Quarterly Activities Report - April 27, 2023

  4/27/2023

  Immutep Limited provides an update on the ongoing development of its product candidates, eftilagimod alpha (efti) and IMP761 for the quarter ended 31 March 2023 (Q3 FY23).

• Quarterly Business Update – March 2023

  4/27/2023

  Genetic Technologies Limited, a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, releases its Appendix 4C and Quarterly business update for the quarter ending 31 March 2023.

• Bionomics Announces the Completion of Enrollment in Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)Topline results expected in Q3 2023

  4/27/2023

  Bionomics Limited announced that the Company has completed target enrollment of approximately 200 participants in its randomized, double-blind, placebo-controlled, multi-center Phase 2b ATTUNE clinical trial evaluating BNC210 in Post-Traumatic Stress Disorder.

• Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology

  4/26/2023

  Alterity Therapeutics today announced that promising wearable sensor data from the Biomarkers of Progression in Multiple System Atrophy (bioMUSE) natural history study was presented at the American Academy of Neurology Annual Meeting.

• Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid

  4/26/2023

  Telix Pharmaceuticals Limited announces the expansion of its artificial intelligence capability with the signing of an agreement to acquire Vienna-based Dedicaid GmbH, a spin-off of the Medical University Vienna.

• Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting

  4/26/2023

  Immutep Limited today announces two abstracts have been selected for poster presentation at the upcoming 2023 American Society of Clinical Oncology’s (ASCO) Annual Meeting, taking place in-person and online from 2-6 June 2023 in Chicago, Illinois (United States).

• Immutep Appoints Dr. Florian Vogl as Chief Medical Officer

  4/26/2023

  Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces that Florian D. Vogl, M.D., Ph.D., MSc, has been appointed as Chief Medical Officer (CMO) with effect from 1 May 2023.

• Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy

  4/21/2023

  Apellis Pharmaceuticals, Inc. today announced that the company has received validation of its marketing applications by regulatory authorities in Canada, Australia, the United Kingdom, and Switzerland for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

• AVITA Medical to Announce First Quarter 2023 Financial Results

  4/20/2023

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) announced today that it will report its first quarter 2023 financial results after the close of the U.S. financial markets on Thursday, May 11, 2023.

• 500 women join Australia's landmark maternity medical device study

  4/19/2023

  Medical device company Baymatob has successfully completed one of Australia's largest maternity health studies for a medical device, enrolling 500 mothers in a pilot study to evaluate its AI-guided labor monitoring device, Oli.

• Publication Validates geneType Prostate Cancer Risk Test

  4/19/2023

  Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce the publication of a research paper in “The Prostate” validating the utilisation of geneType Prostate Cancer Risk Assessment Test in the identification of men who are at increased risk of this serious disease.

• Immuron Q3 FY23 Business Update Presentation

  4/19/2023

  Immuron Limited is pleased to provide the Q3 FY23 Investor Presentation for the business update webinar.